OncoMatch/Clinical Trials/NCT03184753
Genetically Modified T Cells Against Ovarian Cancer
Is NCT03184753 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies OC-IgT cells for ovarian cancer.
Treatment: OC-IgT cells — The primary objectives are to evaluate the safety and efficacy of infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells).
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: salvage treatment — for first recurrence
Complete remission after salvage treatment for first recurrence
Cannot have received: gene-engineered T cell therapy
Previous experience of gene-engineered T cell therapy
Cannot have received: investigational drug
Exception: within the 28-day period prior to Day 0
Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study
Lab requirements
Blood counts
ANC ≥ 1000/mm3; Platelets ≥ 100,000/mm3; Hb ≥ 9 g/dL
Kidney function
Serum creatinine ≤ 2 x ULN; Urine dipstick for proteinuria < 2+ or < 1 g/24 hr if ≥ 2+
Liver function
Serum bilirubin ≤ 2 x ULN (2.0 is acceptable in Gilbert's syndrome); AST/ALT ≤ 2 x ULN; Alkaline phosphatase ≤ 5 x ULN
Adequate bone marrow reserve with ·absolute neutrophil count (ANC) ≥ 1000/mm3. ·Platelets ≥100,000/mm3. Adequate renal and hepatic function with ·Serum creatinine ≤ 2 x upper limit of normal (ULN). ·Serum bilirubin ≤ 2 x ULN. * aspartate aminotransferase (AST)/ALT ≤ 2 x ULN. * Alkaline phosphatase ≤ 5 x ULN. * Serum bilirubin. 2.0 is acceptable in the setting of known Gilbert's syndrome. Exclusion: Inadequate bone marrow function: ·Absolute neutrophil count < 1.0 x 10^9/L. * Platelet count < 100 x 10^9/L. * Hb < 9 g/dL. Inadequate liver and renal function: * Serum (total) bilirubin > 1.5 x ULN. * AST & ALT > 2.5 x ULN (> 5 x ULN in patients with liver metastases). * Alkaline phosphatase > 2.5 x ULN (or > 5 x ULN in case of liver metastases or > 10 x ULN in case of bone metastases). * Serum creatinine >2.0 mg/dl (> 177 μmol/L). * Urine dipstick for protein uria should be < 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate < 1 g of protein/24 hr.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify